Subjects with molecularly defined familial hypercholesterolemia or familial defective apoB-100 are not being adequately treated

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Leren, Trond P ^a   Berge, Knut Erik ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B100; ATORVASTATIN; EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; SIMVASTATIN;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD SAMPLING; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILIAL HYPOBETALIPOPROTEINEMIA; FEMALE; GENE MUTATION; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MOLECULAR DIAGNOSIS; MONOTHERAPY; NORWAY; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PRESCHOOL CHILD; SCHOOL CHILD; SEX DIFFERENCE; DISEASE COURSE; EVALUATION; GENETICS; HYPERLIPOPROTEINEMIA TYPE 2; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; YOUNG ADULT;

EID: 79951968300     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016721     Document Type: Article

References (33)

1. Goldstein JL, Hobbs HH, Brown MS, (2001) Familial hypercholesterolemia. In: Scriver CR, Baudet AL, Sly WS, Valle D, editors. The metabolic basis of inherited disease New York McGraw-Hill pp. 2863-2913.
2. Slack J, (1969) Risks of ischaemic heart disease in familial hyperlipoproteinaemic states. Lancet ii: 1380-1382.
3. Heiberg A, Berg K, (1976) The inheritance of hyperlipoproteinemia with xanthomatosis. A study of 132 kindreds. Clin Genet 9: 203-233.
4. Slack J, (1979) Inheritance of familial hypercholesterolemia. In: Paoletti R, Gotto AM, editors. Atheroscl Rev New York. Raven Press pp. 35-66.
5. Williams RR, Hopkins PN, Hunt SC, Wu LL, Hasstedt SJ, (1990) Population-based frequency of dyslipidemia syndromes in coronary-prone families in Utah. Arch Intern Med 150: 582-588.
6. Koivisto UM, Hämäläinen L, Taskinen MR, Kettunen K, Kontula K, (1993) Prevalence of familial hypercholesterolemia among young north Karelian patients with coronary heart disease: a study based on diagnosis by polymerase chain reaction. J Lipid Res 34: 269-277.
7. Huigen R, Vissers MN, Defesche JC, Lansberg PJ, Kastelein JJ, et al. (2008) Familial hypercholesterolemia: current treatment and advances in management. Expert Rev Cardiovasc 6: 567-581.
8. Williams RR, Hamilton-Craig I, Kostner GM, Hegele RA, Hayden MR, et al. (1996) MED PED: An integrated genetic strategy for preventing early deaths. In: Berg K, Boulyjenkov V, Christen Y, editors. Genetic approaches to noncommunicable diseases Berlin. Springer Verlag pp. 35-46.
9. Neil HAW, Hammond T, Huxley R, Matthews DR, Humphries SE, (2000) Extent of underdiagnosis of familial hypercholesterolemia in routine practice: prospective registry study. BMJ 321: 148.
10. Maarle MCV, Stouthard MEA, Mheen JMVD, Klazinga NS, Bonsel GJ, (2002) Follow up after a family based screening programme for familial hypercholesterolemia: is screening alone enough? BMJ 324: 1367-1368.
11. Umans-Eckenhausen MAW, Defesche JC, Sijbrands EJG, Scheerder RLJM, Kastelein JJP, (2001) Review of the first 5 years of screening for familial hypercholesterolemia in the Netherlands. Lancet 357: 165-168.
12. Umans-Eckenhausen MAW, Defesche JC, van Dam MJ, Kastelein JJP, (2003) Long-term compliance with lipid-lowering medication after genetic screening for familial hypercholesterolemia. Am Med Ass 163: 65-68.
13. Leren TP, Finborud TH, Manshaus TE, Ose L, Berge KE, (2008) Diagnosis of familial hypercholesterolemia in general practice using clinical diagnostic criteria or genetic testing as part of cascade genetic screening. Community Genet 11: 26-35.
14. Scientific Steering Committee on behalf of the Simon Broome Register Group (1991) Risk of fatal coronary heart disease in familial hypercholesterolemia. BMJ 303: 893-896.
15. Defesche J, (2000) Familial hypercholesterolemia. In: Betteridge DJ, editors. Lipids and vascular disease London. Martin Dunitz Ltd pp. 65-76.
16. Leren TP, Berge KE, (2009) Comparison of clinical and molecular genetic criteria for diagnosing familial hypercholesterolemia. Clin Lipidol 4: 303-310.
17. Soria LF, Ludwig EH, Clarke HRG, Vega GL, Grundy SM, et al. (1989) Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100. Proc Natl Acad Sci USA 86: 587-591.
18. Mousavi SA, Berge KE, Leren TP, (2009) The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis. J Intern Med 266: 507-519.
19. Friedewald WT, Levy RI, Fredrickson DS, (1972) Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin Chem 18: 499-502.
20. Law MR, Wald NJ, (1995) An ecological study of serum cholesterol and ischaemic heart disease between 1950 and 1990. Eur J Clin Nutr 49: 221-224.
21. Hoeg J, Feuerstein IM, Tucker EE, (1994) Detection and quantitation of calcific atherosclerosis by ultrafast computed tomography in children and young adults with homozygous familial hypercholesterolemia. Arterioscler Thromb 14: 1066-1074.
22. Pijlman AH, Huigen R, Verhagen SN, Imholz BP, Liem AH, et al. (2010) Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: A large cross-sectional study in The Netherlands. Atherosclerosis 209: 189-194.
23. Daniels SR, Greer FR, (2008) Lipid screening and cardiovascular health in childhood. Pediatrics 122: 198-208.
24. Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Strandberg T, et al. (2010) Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev 7: CD006401.
25. Nozue T, Kawashiri M, Higashikata T, Nohara A, Inazu A, et al. (2006) Cholesterol-years score is associated with development of senile degenerative aortic stenosis in heterozygous familial hypercholesterolemia. J Atheroscler Thromb 13: 323-328.
26. Rallidis L, Naoumova RP, Thompson GR, Nihoyannopoulos P, (1998) Extent and severity of atherosclerotic involvement of the aortic valve and root in familial hypercholesterolemia. Heart 80: 583-590.
27. Tonstad S, Joakimsen O, Stensland-Bugge E, Ose L, Bønaa KH, et al. (1998) Carotid intima-media thickness and plaque in patients with familial hypercholesterolaemia mutations and control subjects. Eur J Clin Invest 28: 971-979.
28. Sidhu PS, Naoumova RP, Maher VM, MacSweeney JE, Neuwirth CK, et al. (1996) The extracranial carotid artery in familial hypercholesterolaemia: relationship of intimal-medial thichness and plaque morphology with plasma lipid and coronary heart disease. J Cardiovasc Risk 3: 61-67.
29. US preventive task force (2007) Screening for lipid disorders in children: US preventive task force statement. Pediatrics 120: e215-219.
30. Wierzbicki AS, Humphries SE, Minhas R, (2008) Familial hypercholesterolaemia: summary of NICE guidance. BMJ 337: 509-510.
31. Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, et al. (2000) Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis. Health Technol Assess 4: 1-123.
32. Wonderling D, Umans-Eckenhausen MA, Marks D, Defesche JC, Kastelein JJ, et al. (2004) Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands. Semin Vasc Med 4: 97-104.
33. Leren TP, (2004) Cascade genetic screening for familial hypercholesterolemia. Clin Genet 66: 483-487.